We have the advantage of owning a library of cancer vaccines, several of which have demonstrated success in human trials. These vaccines were derived from tumor associated antigens (“TAAs”) isolated from the cancer of numerous patients in the 1970s and 1980s, and tested in vaccine clinical trials under the guidance of the FDA.

In these early trials, the vaccines prolonged the survival of cancer patients while causing few side effects. In 2004, Precision Biologics obtained exclusive and full rights to these libraries, which today provide an unmatched platform for the discovery of novel therapeutic candidates.